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Abstract—Nanoparticle drug carriers play an important role
in facilitating efficient targeted drug delivery, i.e., improving
treatment success and reducing drug costs and side effects.
However, the mobility of nanoparticle drug carriers poses a
challenge in designing drug delivery systems. Moreover, healing
results critically depend on the rate and time duration of drug ab-
sorption. Therefore, in this paper, we aim to design a controlled-
release drug delivery system with a mobile drug carrier that
minimizes the total amount of released drugs while ensuring a
desired rate of drug absorption during a prescribed time period.
We model the mobile drug carrier as a mobile transmitter,
the targeted diseased cells as an absorbing receiver, and the
channel between the transceivers as a time-variant channel since
the carrier mobility results in a time-variant absorption rate
of the drug molecules. Based on this, we develop a molecular
communication (MC) framework to design the controlled-release
drug delivery system. In particular, we develop new analytical
expressions for the mean, variance, probability density function,
and cumulative distribution function of the channel impulse
response (CIR). Equipped with the statistical analysis of the CIR,
we design and evaluate the performance of the controlled-release
drug delivery system. Numerical results show significant savings
in the amount of released drugs compared to a constant-release
rate design and reveal the necessity of accounting for drug carrier
mobility for reliable drug delivery.
I. INTRODUCTION
In drug delivery systems, drug molecules are carried to the
diseased cell site by nanoparticle carriers, so that the drug is
efficiently delivered to the targeted site and does not affect
healthy cells [1]. Experimental and theoretical studies have
indicated that not only the total drug dosage but also the
rate and time period of drug absorption by the diseased cell
receptors are critical factors in the healing process [2], [3].
Therefore, it is important to design drug delivery systems with
controlled release to minimize the total amount of released
drugs while achieving a desired rate of drug absorption at the
diseased site during a prescribed time period.
To this end, the mobility of drug carriers has to be accurately
modeled due to the fact that after being injected or extravasated
from the cardiovascular system into the tissue surrounding
a targeted diseased cell site, the drug carriers may not be
anchored at the targeted site but may move, mostly via
diffusion [2], [4]–[6]. The diffusion of the drug carriers results
in a time-variant absorption rate of drugs even if the drug
release rate is constant.
The challenge of designing a controlled-release drug deliv-
ery system has been tackled from two perspectives, namely
mathematical modeling [7] and experiments in vitro and vivo
[8]. In particular, the mathematical approach helps explain
the experimental observations and can guide the experiments.
Recently, researchers have started to design drug delivery sys-
tems based on the molecular communications (MC) paradigm
where drug carriers are modeled as transmitters, diseased cells
are modeled as receivers, and drug absorption is modeled as
a random channel [9]. Controlled-release designs based on an
MC framework were proposed in [10]–[13]. However, in these
works, the transceivers were fixed and only the movement of
drug particles was considered. In contrast, in this paper, we
account for the mobility of the transmitter and analyze the
resulting time-variant MC channel to optimize the controlled-
release design. We note that time-variant MC channels with
mobile transceivers were also considered in [14]–[16]. In
[14], a theory for stochastic time-variant channels in mobile
diffusive MC systems was developed. However, a passive
receiver model was used in [14], which may not be suitable
for modeling drug delivery systems since the effect of drug
absorption cannot be captured. A diffusive absorbing receiver
and the average distribution of the first hitting time, i.e., the
mean of the channel impulse response (CIR), were derived for
a one-dimensional environment without drift in [15] and with
drift in [16]. Clearly, none of these works provides a complete
statistical analysis of the three-dimensional (3D) time-variant
channel with an absorbing receiver nor do they consider drug
delivery systems.
In this paper, we analyze the 3D time-variant channel
with diffusive mobile transmitter and absorbing receiver for
a controlled-release drug delivery system. The main contribu-
tions are as follows:
‚ We design a controlled-release profile that minimizes
the amount of released drugs while ensuring that the
absorption rate at the diseased cells does not fall below
a prescribed threshold for a given period of time. Our
proposed design requires a significantly lower amount of
released drugs compared to a design with constant-release
rate.
‚ We derive the first-order (mean) and second-order (vari-
ance) moments of the time-variant CIR and exploit them
for the design of the controlled-release profile.
‚ We derive the probability density function (PDF) and
the cumulative distribution function (CDF) of the time-
variant CIR for evaluation of the system performance.
‚ The performance of the controlled-release system is eval-
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Fig. 1. System model of controlled-release drug delivery with a diffusive
transmitter (Tx) and an absorbing receiver (Rx).
uated in terms of the probability that the absorption
rate exceeds a targeted threshold. Our results reveal that
considering transmitter mobility is crucial for meeting the
system requirements.
We note that whilst this paper focuses on drug delivery, the
derived analytical results for the mean, variance, PDF, and
CDF of the time-variant CIR are expected to be also useful
for other MC applications.
The remainder of this paper is organized as follows. In
Section II, we introduce the system model. In Section III, we
design the controlled-release profile for a drug delivery system
based on the mean and the variance of the time-variant CIR.
In Section IV, we evaluate the performance of the controlled-
release drug delivery system in terms of the probability that the
absorption rate exceeds a target threshold. Numerical results
are presented in Section V and Section VI concludes the paper.
II. SYSTEM AND CHANNEL MODEL
In this section, we introduce the diffusive mobile MC
system model and define the time-variant CIR of the absorbing
receiver.
A. System Model
We apply an MC design framework to model, analyze, and
optimize a controlled-release drug delivery system, see Fig. 1.
The drug delivery system comprises a drug carrier releasing
drug molecules and diseased cells absorbing them. We model
the system environment as an unbounded 3D diffusion en-
vironment with constant temperature and viscosity. The drug
carriers in drug delivery systems are typically nanoparticles,
such as spherical polymers or polymer chains, having a size
not smaller than 100nm [5]. Hence, we model the drug carrier
as a spherical transmitter, denoted by Tx, with radius atx.
Furthermore, we model the Tx as transparent, i.e., it does
not have any effect on the receiver or drug molecules after
they are released from its center. This model is valid since in
reality the drug carrier is designed to carry drug molecules
and interaction with the drug or the receiver is not intended.
The drug carriers can be directly injected or extravasated from
the blood to the interstitial tissue near the diseased cells (e.g.
a tumor), where they start to move. The movement of the
drug carrying nanoparticles in the tissue is caused by diffusion
and convection mechanisms but diffusion is expected to be
dominant in most cases [2], [4]–[6]. At the tumor site, the
drug carrier releases drug molecules of type X, which also
diffuse in the tissue [2]. Hence, we adopt Brownian motion
to model the diffusion of the Tx and the molecules X [1].
When the drug molecules hit the tumor, they are absorbed
by receptors on the surface of the diseased cells [2], [3]. For
convenience, we model the tumor as a spherical absorbing
receiver, denoted by Rx. In reality, the colony of cancer cells
may potentially have a different geometry, of course. However,
as an abstract approximation, we model the cancer cells as one
effective spherical receiver with radius arx and with a surface
area equivalent to the total surface area of the tumor, i.e.,
the absorption on both the actual and the modeled surfaces is
expected to be comparable [4].
The absorption rate ultimately determines the therapeutic
impact of the drug [2], [3]. Thus, we make achieving a desired
absorption rate the objective for the system design. We will
formally define the absorption rate in the next subsection but
before doing so, we define the parameters and assumptions
used in the system model. We assume that the diffusion of the
Tx and molecules X is independent of each other with cor-
responding diffusion coefficients, DTx and DX, respectively.
We denote the time-varying distance between the centers of the
Tx and the Rx at time t by rptq. In a 3D Cartesian space, rptq
can be represented as rptq “ prx, ry, rzq. Then, the distance
between the centers of the transceivers at time zero is denoted
by rpt “ 0q “ r0 “ prx0, ry0, rz0q. We assume that the
Tx can release molecules during a period of time denoted by
TTx. After this period, the drug carrier may be removed by
blood circulation or run out of drugs. We assume that the Tx
releases molecules at its center instantaneously and discretely
over time. Let ti and ∆ti denote the time instant of the i-th
release and the duration of the interval between the i-th and the
pi` 1q-th release, respectively. We have i P t1, . . . , Iu, where
I is the total number of releases during TTx. We note that a
continuous release can be approximated by letting ∆ti Ñ 0,
i.e., I Ñ 8. Furthermore, let αi and A “
řI
i“1 αi denote
the number of drug molecules released at time ti and the total
amount of drugs released during TTx, respectively.
B. Impulse Response of the Diffusive Channel
To evaluate the drug absorption rate at the Rx given the
drug release profile at the Tx, we first need to derive the
CIR. Let hpt, τq denote the hitting rate, i.e., the absorption
rate of a given molecule, τ [s] after its release at time t at
the center of Tx. Note that the distance between the centers
of the Tx and the Rx, i.e., rptq, is a random variable and a
function of t. Hence, hpt, τq may be referred to as the CIR,
which completely characterizes the time-variant channel. In
hpt, τq, variable t denotes the time instant of the release of the
molecules at Tx while variable τ represents the time period
between the release at the Tx and the absorption at the Rx.
For a given rptq, the CIR hpt, τq is given by [17]
hpt, τq “ arx?
4piDXτ3
ˆ
1´ arx
rptq
˙
exp
˜
´prptq ´ arxq
2
4DXτ
¸
,
(1)
for τ ą 0, and hpt, τq “ 0, for τ ď 0. From the definition
of hpt, τq, for ∆τ Ñ 0, we can interpret hpt, τq∆τ as the
probability of absorption of a molecule by the Rx between
times τ and τ`∆τ after the release at time t. If αi molecules
are released at the Tx at time ti, the expected number of
molecules absorbed at the Rx between times t and t`∆t, for
∆t Ñ 0, is equal to αihpti, t´ tiq∆t, for τ “ t´ ti. During
the period r0, ts, a total amount of At “
ř
i αi,@i|ti ă t,
of drugs are released and thus, an expected total amount of
yptq “ ři αihpti, t ´ tiq∆t,@i|ti ă t, of drugs are absorbed
between times t and t ` ∆t, for ∆t Ñ 0. Let gptq denote
the absorption rate of molecules X at the Rx at time t, i.e.,
gptq “ yptq{∆t, ∆tÑ 0. Then, we have
g ptq “
ÿ
@i|tiăt
αih pti, t´ tiq . (2)
As mentioned before, the absorption rate gptq at the tumor
directly affects the healing efficacy of the drug. Hence, we
will design the drug delivery system such that gptq does not
fall below a prescribed value.
III. CONTROLLED-RELEASE DESIGN
We first formulate the controlled-release design problem
and then derive the mean and variance of the stochastic time-
variant channel to solve the problem.
A. Problem Formulation
The treatment of many diseases requires the diseased cells
to absorb a minimum rate of drugs during a given period of
time [3]. To design an efficient drug delivery system satisfying
this requirement, we optimize the amounts of released drugs
αi such that the total amount of released drugs, A “
řI
i“1 αi,
is minimized and the absorption rate gptq is equal to or larger
than a targeted rate, θptq, for a period of time, denoted by
TRx. Depending on the properties of the tumor, θptq may vary
with time. Since gptq is a random variable, we will design
the system based on the first and second order moments of
the CIR. In particular, we minimize A “ řIi“1 αi subject to
the constraint that the mean of gptq minus a certain deviation
is equal to or above a threshold during TRx, i.e., E tgptqu ´
βΓ tgptqu ě θptq for 0 ď t ď TRx, where E t¨u and Γt¨u
denote expectation and standard deviation, respectively, and
β is a coefficient determining how much deviation from the
mean is taken into account. Based on (2), the constraint can
be written as a function of αi as follows
E tgptqu ´ βΓ tgptqu
paq
ě (3)ÿ
@i|tiăt
αi pE th pti, t´ tiqu ´ βΓ th pti, t´ tiquq ě θptq,
where 0 ď t ď TRx. Inequality paq in (3) is due to
Minkowski’s inequality [18]. Note that we may not be able
to find αi such that (3) holds for all values of β and θptq.
However, when E th pti, t´ tiqu ą βΓ th pti, t´ tiqu, i.e.,
either β or Γ th pti, t´ tiqu is small, so that βΓ th pti, t´ tiqu
is sufficiently small, we can always find αi so that (3) holds for
arbitrary θptq. Since time t is a continuous variable, the con-
straint in (3) has to be satisfied for all values of t, 0 ď t ď TRx,
and thus there is an infinite number of constraints, each of
which corresponds to one value of t. Therefore, we simplify
the problem by relaxing the constraints to hold only for a finite
number of time instants t “ tn “ n∆tn, where n “ 1, . . . , N
and ∆tn “ TRx{N . Then, the optimization problem for the
design of αi can be formulated as
min
αiě0,@i
A “
Iÿ
i“1
αi (4a)
s.t.
ÿ
i,tiăt
αi pm pti, n∆tn ´ tiq ´ βσ pti, n∆tn ´ tiqq
ě θpn∆tn ´ tiq, for n “ 1, . . . , N, (4b)
where m pt, τq and σ pt, τq are the mean and the standard
deviation of h pt, τq, respectively. In order to solve (4), we
need to derive analytical expressions for m pt, τq and σ pt, τq.
Moreover, since h pt, τq is a function of rptq, which is a
random variable, we first need to derive the distribution of
rptq before deriving m pt, τq and σ pt, τq. Having m pt, τq
and σ pt, τq and treating the αi as real numbers, (4) can be
readily solved as a linear program using existing algorithms or
numerical software such as MATLAB. We note that although
the numbers of molecules αi are integers, for tractability, we
solve (4) for real αi and quantize the results to the nearest
integer values.
Note that the problem in (4) is statistical in nature and
provides instructive guidance for the offline design of the
system.
B. Distribution of the Tx-Rx Distance in a Diffusive System
In this subsection, we derive the distribution of rptq. If
the diffusion of Tx follows Brownian motion in the en-
tire 3D environment, we have rx „ N prx0, 2DTxtq , ry „
N pry0, 2DTxtq , rz „ N prz0, 2DTxtq. Then, rptq?
2DTxt
, de-
noted by γ, follows a noncentral chi distribution, denoted by
Xkpλq, [19]
γ “ rptq?
2DTxt
“
d
r2x ` r2y ` r2z
2DTxt
„ Xkpλq, (5)
with parameters k “ 3 and λ “
b
r2x0`r2y0`r2z0
2DTxt
“ r0?
2DTxt
.
Thus, we can obtain the PDF of r as follows
frptqprq paq“
1?
2DTxt
fγ pγq (6)
pbq“ r
r0
?
piDTxt
exp
ˆ
´r
2 ` r2
0
4DTxt
˙
sinh
ˆ
r0r
2DTxt
˙
,
where fγ pγq is the PDF of γ. Equality (a) in (6) exploits the
fact that γ is a function of rptq [20, Eq. 5-16]. Equality (b) in
(6) is obtained from the expression of the PDF fγ pγq [19].
Remark 1: Note that (6) was derived under the assumption
that the Tx can diffuse in the entire 3D environment. In reality,
the Tx cannot be inside the Rx, i.e., it does not interact
with the Rx, and thus will be reflected when it hits the Rx
boundary. Hence, the actual frptqprq may differ from (6), e.g.
frptqprq “ 0 for r ă atx ` arx. However, we note that for
very small r, i.e., r « 0, (6) does approach zero. Hence, (6) is
a valid approximation for the actual frptqprq. The validity of
this approximation is evaluated in Section V via simulations.
C. Statistical Moments of Diffusive Channel
In this subsection, we derive the statistical moments of
the diffusive channel, i.e., mpt, τq and σ2pt, τq. In particular,
mpt, τq is obtained as
mpt, τq “
ż 8
0
hpt, τq ˇˇrptq“r frptqprqdr. (7)
A closed-form expression of (7) is provided in the following
theorem.
Theorem 1: The mean of the impulse response of a time-
variant MC channel with diffusive molecules transmitted by a
diffusive transparent transmitter and absorbed by an absorbing
receiver is given by
mpt, τq “ arx
4
a
pi pDXτ `DTxtqr0τ
exp
ˆ
´ a
2
rx
4DXτ
´ r
2
0
4DTxt
˙
ˆ
˜
´e bpt,τq
2
4apt,τq
ˆ
bpt, τq
2apt, τq ` arx
˙
erfc
˜
bpt, τq
2
a
apt, τq
¸
`e cpt,τq
2
4apt,τq
ˆ
cpt, τq
2apt, τq ` arx
˙
erfc
˜
cpt, τq
2
a
apt, τq
¸¸
,
(8)
where erfcp¨q is the complementary error function and for
compactness, apt, τq, bpt, τq, and cpt, τq are defined as follows
apt, τq “ 1
4DXτ
` 1
4DTxt
, bpt, τq “ ´ arx
2DXτ
´ r0
2DTxt
,
cpt, τq “ ´ arx
2DXτ
` r0
2DTxt
. (9)
Proof: Substituting (1) and (6) into (7) and using the
integrals given by [21, Eq. (2.3.15.4) and Eq. (2.3.15.7)], we
obtain the expression for mpt, τq in (8).
Remark 2: We note that mpt, τq approaches zero when
t Ñ 8 since rptq increases on average due to diffusion.
Next, we obtain the variance of hpt, τq as
σ2ptq “ φptq ´m2ptq, (10)
where φptq “ E  h2pt, τq(. The following lemma gives an
analytical expression for φptq.
Lemma 1: For the considered channel, φptq is given by
φptq “ kˆptq
ż 8
0
”
exp
´
´aˆptqr2 ´ bˆptqr
¯
(11)
´ exp `´aˆptqr2 ´ cˆptqr˘ ıˆr ´ 2arx ` a2rx
r
˙
dr,
where
kˆptq “ a
2
rx
e
´ a
2
rx
2DXτ
´ r
2
0
4DTxt
8DXpiτ3r0
?
piDTxt
, aˆptq “ 1
2DXτ
` 1
4DTxt
,
bˆptq “ ´ arx
DXτ
´ r0
2DTxt
, cˆptq “ ´ arx
DXτ
` r0
2DTxt
. (12)
Proof: Substituting (1) and (6) into the definition of φptq
and simplifying the expression, we obtain (11).
Remark 3: The expression in (11) comprises integrals of
the form
ş8
0
exp
`
ax2 ` bx˘ {x dx, where a and b are con-
stants, and cannot be obtained in closed form. However, these
integrals can be evaluated numerically in a straight forward
manner.
IV. PERFORMANCE ANALYSIS
Since gptq is random, we cannot always guarantee gptq ě
θptq. Moreover, since gptq ě θptq is required for proper
operation of the system, we evaluate the system performance
in terms of the probability that gptq ě θptq, denoted by Pθ “
Pr tgptq ě θptqu. In this section, we first present a theoretical
framework for evaluation of the system performance in terms
of Pθ expressed as a function of the PDF and CDF of the
CIR, before finally deriving the PDF and CDF of the CIR.
A. System Performance
The probability Pθ is given in the following theorem.
Theorem 2: The system performance metric Pθ can be
expressed as
Pθ “1´ fα1hpt´t1,t1q pθptqq ˚ ¨ ¨ ¨ ˚ fαiˇ´1hpt´tiˇ´1,tiˇ´1q pθptqq
˚ Fαiˇhpt´tiˇ,tiˇq pθptqq , (13)
where ˚ denotes convolution, iˇ “ 1, 2, . . . satisfies tˇi ď t,
and ft¨u and Ft¨u denote the PDF and CDF of the ran-
dom variable in the subscript, respectively. In (13), we de-
fine fαiˇhpt´tiˇ,tiˇq pθptqq “ 1{αiˇ ˆ fhpt´tiˇ,tiˇq pθptq{αiˇq and
Fαiˇhpt´tiˇ,tiˇq pθptqq “ Fhpt´tiˇ,tiˇq pθptq{αiˇq.
Proof: From the definition of the CDF, we have
Pθ “ 1´ Fgptq tθptqu “ 1´
ż θptq
0
fgptqpgqdg. (14)
Due to the summation of independent random variables in (2),
i.e., independent releases at ti, we have
fgptqpgq “
`
fα1hpt´t1,t1q ˚ ¨ ¨ ¨ ˚ fαiˇhpt´tiˇ,tiˇq
˘ pgq. (15)
Substituting (15) into (14), and using the integration property
of the convolution, i.e.,ż θptq
0
`
fα1hpt´t1,t1q ˚ ¨ ¨ ¨ ˚ fαiˇhpt´tiˇ,tiˇq
˘ pgqdg (16)
“ fα1hpt´t1,t1q pθptqq ˚ ¨ ¨ ¨ ˚
ż θptq
0
fαiˇhpt´tiˇ,tiˇqpgqdg,
and using the definition of the CDF, we obtain (13).
According to (13), Pθ can be evaluated based on exact
expressions for the PDF and the CDF of hpt, τq, which will
be derived in the next subsection.
Furthermore, we note that a minimum value of Pθ can be
guaranteed based on statistical moments of the CIR, without
knowledge of the PDF and the CDF, as shown in the following
proposition.
Proposition 1: A lower bound on Pθ “ Pr tgptq ě θptqu is
given as follows
Pθ ě 1´ 1
β2
. (17)
Proof: By using (3) and the Chebyshev inequality [20],
we obtain
Pθ
paq
ě Pr
!
|gptq ´ E tgptqu| ď E tgptqu ´ θptq
)
(18)
pbq
ě 1´ Γ
2 tgptqu
pE tgptqu ´ θptqq2
pcq
ě 1´ 1
β2
,
where (a) can be obtained easily by expanding the absolute
value on the right-hand side, (b) is due to the Chebyshev
inequality, and (c) is due to (3). This completes the proof.
Remark 4: Proposition 1 is not only useful for evaluating
the system performance, but also provides a guideline for the
design of the controlled release of drugs. For example, to
ensure Pθ ě 0.75, from (17), we obtain β “ 2. Note that a
useful bound can only be obtained based on (17) when β ą 1.
B. Distribution Functions of the CIR
The PDF of the CIR is given in the following theorem.
Theorem 3: The PDF of the impulse response of a time-
variant channel with diffusive molecules transmitted by a
diffusive transparent transmitter and absorbed by an absorbing
receiver is given by#
fhprptq,τqphq “ frptqpr1phqqh1pr1phq,τq ´
frptqpr2phqq
h1pr2phq,τq , for 0 ď h ă h‹,
fhprptq,τqphq Ñ 8, for h “ h‹,
(19)
where h prptq, τq denotes h pt, τq as a function of rptq and
τ , frptqprq is given by (6), r1phq and r2phq, r1phq ă r2phq,
are the solutions of the equation h prptq, τq “ h, h‹ is the
maximum value of h prptq, τq for all values of rptq, and
h1pr, τq is given by
h1pr, τq “ arx?
4piDXτ3
exp
˜
´pr ´ arxq
2
4DXτ
¸
(20)
ˆ
ˆ
arx
r2
´ pr ´ arxq
2DXτ
´
1´ arx
r
¯˙
.
Proof: From (20), we observe that h1pr, τq “ Bhpr,τqBr “ 0
is equivalent to a cubic equation in r, given by ar3 ` br2 `
cr ` d “ 0, with properly defined coefficients a, b, c, d and
discriminant ∆ “ 18abcd´4b3d` b2c2´4ac3´27a2d2 ă 0.
Hence, h1pr, τq “ 0 has only one real valued solution, denoted
by r‹. Then, from (20), we obtain that h1pr1, τq ą 0 for r1 ă
r‹, h1pr2, τq ă 0 for r2 ą r‹, and h1pr, τq “ 0 for h “ h‹,
where h‹ “ h pr‹, τq is the maximum value of hpr, τq. Finally,
we derive (19) by exploiting [20, Eq. 5-16] for the PDF of
functions of random variables.
The CDF of hpt, τq is given in the following corollary.
Corollary 1: The CDF of the impulse response of a time-
variant channel with diffusive molecules transmitted by a
diffusive transparent transmitter and absorbed by an absorbing
receiver is given by
Fhprptq,τqphq “ Frptqpr1phqq ` 1´ Frptqpr2phqq, (21)
for 0 ď h ď h‹, where Frptqprq is the CDF of r and is given
by
Frptqprq “ 1´Q 3
2
ˆ
λ,
r?
2DTxt
˙
. (22)
Here, λ is defined in (5) and QM pa, bq is the Marcum Q-
function as defined in [19].
Proof: From the definition of the CDF and (19), we have
Fhprptq,τqphq “
ż h
0
fhprptq,τqphˇqdhˇ (23)
“
ż h
0
frptqprˇ1phˇqq
Bhprˇ1, τq{Brˇ1 ´
frptqprˇ2phˇqq
Bhprˇ2, τq{Brˇ2 dhˇ
“
ż r1phq
0
frptqprˇ1qdrˇ1 ´
ż r2phq
8
frptqprˇ2qdrˇ2
“Frptqpr1phqq ` 1´ Frptqpr2phqq,
where rˇ1 and rˇ2, rˇ1 ă rˇ2, are the solutions of the equation
h prˇ, τq “ hˇ. Moreover, since rptq?
2DTxt
follows a noncentral chi
distribution, we obtain (22) as [19]
Frptqprq “ F rptq?
2DTxt
ˆ
r?
2DTxt
˙
“ 1´Q 3
2
ˆ
λ,
r?
2DTxt
˙
.
(24)
This completes the proof.
We note that the analytical expressions for the PDF and
CDF of hpt, τq in Theorem 3 and Corollary 1, respectively,
are not in closed form. Therefore, the evaluation of the
system performance in (13) can be approximated by a discrete
convolution which is easily evaluated numerically.
Remark 5: The results for the mean, variance, PDF, and
CDF of the CIR in Sections III-C and IV-B can also be applied
for applications where both the transmitter and the receiver
undergo diffusion. In this case, we have to replace DX and
DTx in the derived expressions by D1 “ DX ` DRx and
D2 “ DTx `DRx, respectively. D1 and D2 are the effective
diffusion coefficients capturing the relative movements of the
molecules X and the Rx and the relative movements of the
Tx and the Rx, respectively, see [14].
V. NUMERICAL RESULTS
In this section, we provide numerical results to evaluate
the accuracy of the derived expressions and the efficiency of
the proposed drug delivery system. In the simulations, we use
a particle-based simulation of Brownian motion, where the
transmitter performs a random displacement in discrete time
steps of length ∆tst seconds. The random displacement of
the transmitter in each step is modeled as a Gaussian random
variable with zero mean and standard deviation
?
2DTx∆tst.
Furthermore, in the simulations, we also take into account the
reflection of the Tx when the Tx hits the Rx. Moreover, we
adopt Monte-Carlo simulation by averaging our results over a
large number of independent realizations of the Tx movement.
For all numerical results, we use the set of simulation
parameters in Table I, unless otherwise stated. The parameters
in Table I are chosen to match real system parameters, e.g.
the diffusion constants DX of drug molecules vary from 10
´9
to 10´14 m2{s [6], the drug carriers have sizes ě 100 nm [5],
the size of tumor cells is on the order of µm, and the drug
carriers can be injected or extravasated from the cardiovascular
system in the tissue surrounding the targeted diseased cell
site [2], i.e., close to the tumor cells. The dosing periods
in drug delivery systems are on the order of days [7], i.e.,
24 h. For simplicity, we set ∆ti “ TTx{I,@i P t1, . . . , Iu,
and N “ 5, and the value of the required absorption rate is
TABLE I
SYSTEM PARAMETERS USED FOR NUMERICAL RESULTS
Parameter Value Parameter Value
DX [m
2{s] 8ˆ 10´11 DRx [m
2{s] 0
atx [m] 1ˆ 10´7 arx [m] 1ˆ 10´6
TTx [h] 24 TRx [h] 24
r0 [m] 10ˆ 10´6 N 5
I 3000 θptqrs´1s 1
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3,000
4,000
5,000
6,000
DTx = 10
−14m2/s
DTx = 5× 10
−14m2/s
DTx = 10
−13m2/s
DTx = 0m
2/s
Benchmark
Release time ti [h]
α
i
β = 0
β = 0.4
β = 1
β = 2
Fig. 2. Optimal release coefficients αi as a function of release time ti
[h] for different system parameters. The black horizontal dotted line is the
benchmark when the αi are not optimized.
set to θptq “ 1 s´1. We choose I relatively large to obtain
small intervals ∆ti. All simulation results are averaged over
105 independent realizations of the environment.
In Fig. 2, we plot the controlled-release coefficients αi
versus the corresponding release time ti [h] for different
system parameters. The coefficients are obtained by solving
the optimization problem in (4) with β “ t0, 0.4, 1, 2u for
DTx “ 10´14 m2{s and β “ t0, 0.4u for DTx “ t5, 10u ˆ
10´14 m2{s. As mentioned in the discussion of (3), we cannot
choose large values of β when the diffusion coefficient is
large, i.e., the standard deviation is large, as the problem
may become infeasible. Fig. 2 shows that for all considered
parameter settings, we should first release a large number of
molecules for the absorption rate to exceed the threshold.
Then, in the static system with DTx “ 0m2{s, the optimal
coefficient decreases with increasing time, since a fraction of
the molecules previously released from the Tx linger around
the Rx and are absorbed later. However, for the mobile time-
variant channels, the Tx eventually diffuses away from the
Rx as time t increases and hence, molecules released at later
times by the Tx are far away from the Rx and may not reach
the Rx. Therefore, at later times, the amount of drugs released
has to be increased for the absorption rate to not fall below
the threshold. For higher DTx, the Tx diffuses away from the
Rx faster and thus, the coefficients αi have to increase faster.
This type of drug release is called a tri-phasic release [8].
Once we have designed the controlled-release profile, we can
implement this by choosing a suitable drug carrier as shown in
[8]. Moreover, as expected, with larger β, we need to release
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Fig. 3. E tgptqu and Γ tgptqu between the 1000-th release and the 1002-
th release, i.e., at about 8 h, for three different designs. Design 1 (green
line): naive design without considering Tx movement with DTx “ 10
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more drugs to ensure that (4) is feasible. The black horizontal
dotted line in Fig. 2 is a benchmark where the αi,@i, are not
optimized but naively set to αi “ α1. For this naive design,
A “ α1I « 1.65 ˆ 107, whereas with the optimal αi, for
β “ 0 and DTx “ 10´13 [m2{s], A “ 1.2 ˆ 107, i.e., equal
to 73% of the naive design, and for β “ 1 and DTx “ 10´14
[m2{s], A “ 7.6ˆ106, i.e., equal to 46% of the naive design.
This highlights that applying the optimal controlled-release
profile can save significant amounts of drugs and still satisfy
the therapeutic requirements. Moreover, as observed in Fig. 2,
the required values of αi increase as ti increases and thus
the naive design with fixed αi, i.e., the benchmark, cannot
ultimately satisfy the required absorption rate.
In Fig. 3, we plot the mean and standard deviation of the
absorption rate, E tgptqu and Γ tgptqu, between the 1000-th
release and the 1002-th release for three designs, where we
adopted DTx “ 10´13 m2{s and β “ 0 for designs 1 and
2, and DTx “ 10´14 m2{s and β “ 1 for design 3. Note
that the considered time window, e.g., between the 1000-th
release and the 1002-th release, is chosen arbitrarily in the
middle of TTx to analyze the system behavior. For design 1,
the Tx diffuses with DTx “ 10´13 m2{s but the controlled
release is designed without accounting for the Tx mobility,
i.e., the adopted αi are given by the green line in Fig. 2
obtained under the assumption of DTx “ 0m2{s. For designs
2 and 3, the mobility of the Tx is taken into account. The
black dashed line marks the threshold θptq that gptq should
not fall below. It is observed from Fig. 3 that when the Tx
diffuses but the design does not take into account the mobility,
the requirement that the expected absorption rate, E tgptqu,
exceeds θptq, is not satisfied for most of the time. For design 2
with β “ 0, we observe that E tgptqu ą θptq always holds but
E tgptqu´Γ tgptqu ą θptq does not always hold. For design 3
with β “ 1, we observe that E tgptqu´Γ tgptqu ą θptq always
holds since β ą 0 enforces a gap between E tgptqu and θptq. In
other words, even if gptq deviates from the mean, it can still
exceed θptq. Fig. 3 also shows that E tgptqu first increases
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after a release and then decreases, due to the diffusion of
the molecules. Furthermore, Fig. 3 confirms the accuracy of
our derivations as the simulation results match the analytical
results. Note that in the simulations, unlike the analysis, we
have considered the reflection of the Tx when it hits the Rx.
Therefore, the good agreement in Fig. 3 suggests that the
reflection of the Tx does not have a significant impact on
the numerical results and the approximation in (6) is valid.
In Fig. 4, we present the system performance in terms of Pθ,
for the time period between the 1000-th and 1002-th releases,
i.e., at about 8h. The lines and markers denote simulation and
analytical results, respectively. Fig. 4 shows a good agreement
between the analytical and simulation results. In Fig. 4, we
observe that Pθ increases with increasing β because the design
for larger β enforces a larger gap between E tgptqu and θptq,
as can be seen in Fig. 3. Moreover, for a given β, Pθ will be
different for different DTx. In particular, for larger DTx, Pθ is
smaller due to the faster diffusion and less certainty about the
CIR. Moreover, in Fig. 4, the green line shows that the naive
design, i.e., design 1 in Fig. 3, has very poor performance.
In Fig. 4, we also observe that between two releases, Pθ first
increases due to the released drugs and then decreases due
to drug diffusion. Furthermore, in Fig. 4, we show the lower
bound on Pθ derived in Proposition 1 for DTx “ 10´14 m2{s
and β “ 2, where (17) yields Pθ ě 0.75. Fig. 4 shows that
the red dash-dotted line, i.e., Pθ for DTx “ 10´14 m2{s and
β “ 2, is above the horizontal black dashed line, i.e., Pθ “
0.75.
VI. CONCLUSIONS
In this paper, we considered a drug delivery system with a
diffusive drug carrier and absorbing cells and modeled it as a
time-variant channel between diffusive MC transceivers. We
provided a statistical analysis of the time-variant CIR. Based
on this statistical analysis, we designed the optimal controlled-
release profile which minimizes the amount of released drugs
while ensuring a targeted absorption rate of the drugs at the
Rx for a prescribed time period. The probability of satisfying
the constraint on the absorption rate was adopted as a system
performance criterion and was evaluated. We observed that
ignoring the reality of Tx mobility in designing the release
profile leads to unsatisfactory performance.
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